Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Fimbrion, GSK Research Alliance Identifies Novel UTI Treatment | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Fimbrion, GSK Research Alliance Identifies Novel UTI Treatment

Candidate represents a new strategy for treating bacterial infections

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Fimbrion Therapeutics, Inc., under its joint research collaboration with GlaxoSmithKline, has identified an orally available, small molecule development candidate for the treatment and prevention of urinary tract infections (UTIs). The Discovery Partnership began its joint research efforts in July 2016. 
 
The newly identified clinical candidate is a mannose-containing small molecule that targets an adhesive protein in bacteria called FimH. This drug candidate represents a new strategy for treating bacterial infections by preventing the bacteria that cause UTIs from sticking to the walls of the bladder, allowing the body to naturally eliminate the infection. Since this mannose-containing compound does not kill bacteria, it potentially could treat and prevent UTIs without inducing antibiotic resistance.
 
“We are thrilled to have hit this candidate selection milestone with GSK,” said Dr. Scott Hultgren, co-founder and board member of Fimbrion, said. “Our collaboration demonstrates the true power of working together in the face of the imminent antibiotic resistance crisis—combining great science from academic research, the energy of an entrepreneurial start-up, and the expertise and resources of a world leading global healthcare company to deliver a new antimicrobial therapy.” Dr. Hultgren is the principal investigator for the collaboration with GSK, and he is a member of the National Academy of Sciences and National Academy of Medicine.
 
Gram-negative bacteria are the primary cause of UTIs. Options for treating UTIs and other Gram-negative bacterial infections have become increasingly limited due to the increase in antibiotic resistance. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics